Resistant prolactinomas

Potential Cardiac Valve Effects of Dopamine Agonists in Hyperprolactinemia

(2010) Elena Valassi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study

(2010) Adrian F. Daly et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide-induced inhibition of pituitary adenoma cells

(2010) Jason Sheehan et al.   JOURNAL OF NEUROSURGERY

The prolactinoma

(2009) Annamaria Colao   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Evolution of an Aggressive Prolactinoma into a Growth Hormone Secreting Pituitary Tumor Coincident with GNAS Gene Mutation

(2009) Andrea G. Lania et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A novel use of temozolomide in a patient with malignant prolactinoma

(2009) Stephen Byrne et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Cabergoline and the risk of valvular lesions in endocrine disease.

(2008) Patrizio Lancellotti et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas

(2008) Alessandra Fusco et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients

(2008) Masami Ono et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Genes Differentially Expressed in Prolactinomas Responsive and Resistant to Dopamine Agonists

(2008) Vanessa Q. Passos et al.   NEUROENDOCRINOLOGY

Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas

(2008) M Filopanti et al.   PHARMACOGENOMICS JOURNAL